Skip to main content
Brendan Weiss, MD, Oncology, Philadelphia, PA, Providence Veterans Affairs Medical Center

BrendanMWeissMD

Oncology • Philadelphia, PA

Hematologic Oncology

Assistant Professor, Medicine, Perelman School of Medicine, University of Pennsylvania

Join to view full profile

Dr. Weiss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Weiss' full profile

Already have an account?

  • Office

    3400 Civic Center Boulevard
    Perelman Center for Advanced Medicine - 2 West
    Philadelphia, PA 19104
    Phone+1 215-615-5853
    Fax+1 215-615-5887
  • Is this information wrong?

Summary

  • Current research
    I am a hematologist-oncologist with a specific research and clinical interest in plasma cell disorders and related dysproteinemias: multiple myeloma, immunoglobulin light chain (AL) amyloidosis, and Waldenstrom’s macroglobulinemia.

    I also lead the multi-disciplinary Penn Amyloidosis Program. This is a cross-disciplinary program involving clinicians with expertise in amyloidosis from cardiology, nephrology, pathology and other disciplines.

    I am involved in clinical, translational and epidemiologic research throughout the spectrum of plasma cell disorders. My primary research focus is on the myeloma precursor states: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). I have previously established that both multiple myeloma (Weiss Blood 2009) and AL amyloidosis (Weiss J Clin Oncol 2014) have precursor states that are detectable for many years prior to diagnosis. I have also validated biomarkers for ultra-high risk SMM (Waxman Leukemia 2014) that have contributed to changing the diagnostic criteria for multiple myeloma requiring treatment (Rajkumar Lancet Oncol 2014).

    I am currently performing trials to develop and test novel biomarkers for progression in the myeloma precursor states (MGUS and SMM). I am also participating in trials of early intervention in high risk SMM.

    I am also conducting trials of novel agents for AL amyloidosis and relapsed and refractory multiple myeloma.

Education & Training

  • San Antonio Uniformed Services Health Education Consortium
    San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1998 - 2001
  • UniforMed Services University of the Health Sciences F. Edward Hebert School of Medicine
    UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1998
  • Bucknell University
    Bucknell UniversityBS, Biology, 1989 - 1993
  • National Capital Consortium
    National Capital ConsortiumFellowship, Hematology and Medical Oncology

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2011 - 2022
  • NY State Medical License
    NY State Medical License Active through 2013

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • New Studies from Penn Medicine Yield New Hope for AL Amyloidosis Patients
    New Studies from Penn Medicine Yield New Hope for AL Amyloidosis PatientsDecember 5th, 2016
  • With Promising Results from Emerging Therapies, Penn Research Yields Fresh Hope for Treatment of Rare Disease AL Amyloidosis
    With Promising Results from Emerging Therapies, Penn Research Yields Fresh Hope for Treatment of Rare Disease AL AmyloidosisDecember 1st, 2016

Professional Memberships

Hospital Affiliations

External Links

  • Penn Amyloidosis Programhttp://www.pennmedicine.org/hematology-oncology/patient-care/clinical-programs/amyloidosis-program/

Dr. Brendan Weiss, Dr. Brendan Weiss, MD, Dr. B Weiss, Dr. Brendan M Weiss